News

Article

Elevated Non-HDL Cholesterol a Stronger Indicator of Major Cardiovascular Events Compared With LDL-C

Key Takeaways

  • Non-HDL-C is a better predictor of MACE than LDL-C in statin-treated patients with ASCVD or high ASCVD risk.
  • The study found a significant correlation between higher non-HDL-C levels and increased MACE risk, unlike LDL-C levels.
SHOW MORE

Non-high-density lipoprotein cholesterol was found to be more effective at predicting cardiovascular events such as stroke, myocardial outcomes, heart failure, and others compared with low-density lipoprotein cholesterol.

Results of a new study published in the Journal of Clinical Lipidology indicate that non-high-density lipoprotein cholesterol (non-HDL-C), which is the sum of cholesterol content carried by low-density lipoprotein (LDL), triglyceride-rich lipoproteins (TRL), and lipoprotein (a), is a better indicator of major adverse cardiovascular events (MACE) in statin-treated patients with atherosclerotic cardiovascular disease (ASCVD) or those with a high risk of ASCVD compared with LDL cholesterol (LDL-C) alone.1,2

Cholesterol plaque in artery

LDL-C is known as "bad" cholesterol and is a predictor of adverse health outcomes. | Image Credit: © hywards - stock.adobe.com

For decades, LDL-C has been established in clinical guidelines as a major factor contributing to ASCVD risk, with countless randomized studies demonstrating an association between lowering LDL-C and reducing the risk of cardiovascular events. Triglyceride levels have also been linked to adverse CVD events, with one study finding that a high triglyceride to HDL-C ratio had meaningful associations with the incidence of MACE and cardiac death.1,3

Increasingly, many guidelines are including non-HDL-C as an additional marker that, when reduced, can lower cardiovascular risk. One analysis, conducted by Hansen et al., contributed to current literature by reporting non-HDL-C as an easily accessible marker for detecting patients with a high residual risk of ASCVD and death in those undergoing lipid-lowering therapy having already achieved their LDL-C targets. Another large study found that individuals with higher non-HDL-C levels had a heightened long-term risk of adverse outcomes such as myocardial infarction and stroke.1,2,4

Still, there are scarce prospective long-term studies, especially in cohorts of Asian populations, that evaluate the association between non-HDL-C and LDL-C levels and MACE in statin-treated patients with or at high risk of ASCVD. Therefore, in this current trial, the predictive abilities of each lipoprotein measure were compared in a large cohort of patients in Thailand 45 years and older with confirmed ASCVD or multiple ASCVD risk factors.2

The outcomes of the trial included 3-point MACE, which comprises all-cause mortality, non-fatal myocardial infarction, and nonfatal stroke, and other incidences of myocardial infarction, heart failure, strokes, and overall mortality, according to the investigators. In this post-hoc analysis, which utilized a registry of Thai citizens at risk for cardiovascular events, a total of 8245 patients that had successfully completed statin therapy were included, of which 6978 had complete non-HDL-C data and 7365 had complete LDL-C data.1

Across the follow-up period, study authors observed 776 patients with complete non-HDL-C data and 833 patients with complete LDL-C data developing 3P-MACE. Using a fully adjusted model, they determined that higher non-HDL-c levels were significantly correlated with a higher risk of 3P-MACE (HR: 1.008; 95% CI, 1.003-1.012; P<.001). Furthermore, for each additional increment in non-HDL-C levels, the risk of 3P-MACE further increased (HR: 1.120; 95% CI, 1.052-1.195; P<.001). In an interesting development, increasing LDL-C levels showed no significant association with 3P-MACE (HR: 0.995; 95% CI, 0.989-1.000; P=.072), with similar results when calculated using increasing incremenets.1

In their discussion, the investigators noted that the association between non-HDL-C and ASCVD was sustained even throughout subgroup analyses and in patients who achieved an LDL-C target of less than 70 mg/dL. Accordingly, the investigators believe that non-HDL-C can be a more significant predictor of future CV events than LDL-C, especially in Asian cohorts previously treated with statins. They attribute this strong predictive value with the comprehensiveness of non-HDL-c, which incorporates multiple cholesterol risk factors into one measurement.1

“Due to its ease of use, non-HDL-C could serve as a potential marker or a better primary target for residual risk in statin-treated Asian patients, helping to lower cardiovascular risk,” the study authors concluded. “Future non-observational studies are warranted to establish the causal relationship of this finding.”1

REFERENCES
1. Manosroi W, Phinyo P, Phimphilai M, et al. Non-high-density lipoprotein cholesterol outperforms low-density lipoprotein cholesterol in predicting cardiovascular events among high-risk Asians. Journ Clin Lipidology. 2025. doi:10.1016/j.jacl.2025.01.002
2. Gallagher A. Investigators find the triglyceride/high density lipoprotein cholesterol ratio is significantly associated with MACE. Pharmacy Times. Published January 8, 2025. Accessed March 21, 2025. https://www.pharmacytimes.com/view/investigators-find-triglyceride-high-density-lipoprotein-cholesterol-ratio-is-significantly-associated-with-mace
3. Hansen MK, Mortensen MB, Olesen KKW, et al. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study. The Lancet Europe. 2024;36:100774. doi:10.1016/j.lanepe.2023.100774
4. Hong S, Han K, Park JW, et al. Higher non-high-density lipoprotein cholesterol was higher associated with cardiovascular disease, comparing higher LDL-C in nine years follow up: Cohort study. J Lipid Atheroscler. 2023;12(2):164-174. doi:10.12997/jla.2023.12.2.164

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Image credit: Dr_Microbe | stock.adobe.com